| Literature DB >> 33456250 |
Rizwan M Sanadi1, Revati S Deshmukh2.
Abstract
Vitamin C, also known as ascorbic acid, is used as a treatment modality in depigmentation of hyperpigmented spots on the skin and gingiva. This systematic review discusses the studies conducted to assess the effect of Vitamin C on melanin pigmentation. The primary objective was to evaluate the effect of Vitamin C on melanin pigmentation. The secondary objective was to analyze the effect of Vitamin C administration on melanin pigmentation. An electronic database search was conducted from the following databases: PubMed, EBSCOhost, ScienceOpen, EMBASE and Google Scholar. Randomized controlled trials, experimental studies, case-control studies and cohort studies published in peer-reviewed journals in English language were included. Case reports, case series, animal model studies, in vitro studies, studies where Vitamin C was used along with other agents and unpublished research were excluded. Out of 22,580 studies, only 7 studies satisfied the selection criteria. Data extraction sheet was prepared, and the studies were analyzed. Out of the 7 studies analyzed, 1 was a randomized controlled trial and 6 were experimental studies. Vitamin C has been used widely as a depigmenting agent in dermatology. However, there are limited studies conducted on the use of Vitamin C for gingival depigmentation. Copyright:Entities:
Keywords: Ascorbic acid; Vitamin C; depigmentation; gingival melanin hyperpigmentation; melanin pigmentation; melanogenesis; tyrosinase
Year: 2020 PMID: 33456250 PMCID: PMC7802860 DOI: 10.4103/jomfp.JOMFP_207_20
Source DB: PubMed Journal: J Oral Maxillofac Pathol ISSN: 0973-029X
Figure 1Flow chart of literature search results and study selection
Characteristics of the studies included in the Systematic Review
| Authors & Year of Publication | Country | Aim | Tissue assessed Gingiva/Skin | Type of study | Sample size, Comparison group & control group | Methodology | Conclusion |
|---|---|---|---|---|---|---|---|
| Shimada Y, Tai H, Tanak A, Suzuki I, Takagi K (2009) 16 | Japan | To investigate the inhibitory effects of a gel containing ascorbic acid 2-glucoside (AS-G gel) on gingival melanin pigmentation. | Gingiva | Double-masked placebo- controlled clinical trial, split-mouth design (randomised controlled trial) | 73 subjects with symmetric gingival melanin pigmentation. | AS-G test gel was applied to left the side and placebo gel was applied to the right side of the gingiva. | Ascorbic acid (AS-G) seems to have potential for the treatment of gingival melanin pigmentation at home. |
| Yussif NM, Zayed SO, Hasan SA, Sadek SS (2016) 5 | Cairo University, Egypt | To evaluate the efficiency of injectable Vitamin C as a depigmenting agent in physiologic gingival hyperpigmentation | Gingiva | Experimental Study | 40 patients in age range of 20-44 years with physiologic gingival melanin hyperpigmentation | A 200-300mg (1-1.5 ml) ascorbic acid (ampoule) was injected in the gingival tissues once per week until no visible pigmentation. | Vitamin C injection is a safe, minimally invasive non-surgical depigmenting technique for gingival tissue. |
| Yussif NM, Abdel Rahman AR, Elbarbary E (2019)17 | Cairo University, Egypt | To evaluate the efficacy of intra-epidermal vitamin C injection in comparison to the conventional surgical technique in gingival hyperpigmentation | Gingiva | Experimental Study | 30 patients with mild to severe hyperpigmented gingival tissues were divided into Group 1(Control group-conventional scalpel depigmentation performed) & Group 2(Test group- Vitamin C was injected intra-epidermal) | Maximum 0.1 ml of ascorbic acid was recommended for each point with 2-3 mm apart. | Usage of vitamin C injection for depigmentation showed comparative results to the conventional surgical technique. |
| Ratnam AV, Sastry PB, Satyanarayana BV (1977)18 | India | To estimate tde content of ascorbic acid in normal pigmented skin in comparison to the depigmented skin of vitiligo. | Skin | Experimental study | Control group-10 subjects with normal pigmented skin. Study group-12 vitiligo cases with variable loss of pigmentation and 1 was albino. | The estimations of ascorbic acid levels were repeated after saturation with daily doses of 70 mg ascorbic acid per stone body weight. | Ascorbic acid has an important role to play in the metabolic functions of the epidermis, the most important of these being keratinization and melanogenesis. |
| Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M (1996)19 | California | To examine the effect on pigmentation of magnesium-L-ascorbyl-2-phosphate (VC-PMG), a stable derivative of Ascorbic acid. | Skin | Experimental study | 34 patients with phelides. chloasma, senile freckles, nevus of Ota, or healthy skin | VC-PMG cream 10% was applied twice a day to the skin. | VC-PMG was effective in lightening the skin of some patients with hyperpigmentation disorders and some subjects with normally pigmented healthy skin. |
| Kim HM, An HS, Bae JS, Kim JY, Choi CH, Kim JY (2017)20 | Korea | To investigate the effects of palmitoyl-KVK-L-ascorbic acid on skin aging, the anti-wrinkle and depigmentation. | Skin | Experimental study | 21 healthy Korean women aged between 41 and 55 years | The cream with 0.075% (0.75 mg/mL) of Palm-KVK-AA or without Palm-KVK-AA was applied to each half of the participant’s face, twice daily for 12 weeks. The allocation of the cream was based on a double-blind randomized method. | Palmitoyl-KVK-L-ascorbic acid is an effective anti-aging agent that reduces wrinkles and abnormal skin pigmentation. |
| Jaros A, Zasada M, Budzisz E, Debowska R, Rzepka MG, Rotsztejn H (2019)21 | Poland | To evaluate selected capillary skin parameters after applying 5% vitamin C concentrate. | Skin | Experimental study | (50.1 ± 3.9 years) 30 women of 30-60 years of age with capillary skin indicating visible signs of erythematous plaques. Control group of 11 patients | The participants were instructed to use 5% Vitamin C concentrate once a day during the evening and apply it on their facial skin. | 5% Vitamin C concentrate is very effective in treating Erythema as well as decreasing the visibility of telangiectasia |
Risk of Bias of the studies included in the Systematic Review
| Author (Year) | Type of study | Random sequence generation | Allocation concealment | Blinding of participants | Blinding of outcome | Incomplete outcome data | Selective reporting |
|---|---|---|---|---|---|---|---|
| Shimada Y, Tai H, Tanak A, Suzuki I, Takagi K (2009)16 | Randomized controlled clinical trail | yes | yes | yes | not clear | not clear | not clear |
| Yussif NM, Zayed SO, Hasan SA, Sadek SS (2016)5 | Experimental study | yes | yes | not clear | not clear | not clear | not clear |
| Yussif NM, Abdel Rahman AR, Elbarbary E (2019)17 | Experimental study | no | no | no | no | no | not clear |
| Ratnam AV, Sastry PB, Satyanarayana BV (1977)18 | Experimental study | no | no | no | no | no | not clear |
| Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M (1996)19 | Experimental study | no | no | no | no | no | not clear |
| Kim HM, An HS, Bae JS, Kim JY, Choi CH, Kim JY (2017)20 | Experimental study | not clear | not clear | yes | yes | not clear | not clear |
| Jaros A, Zasada M, Budzisz E, Debowska R, Rzepka MG, Rotsztejn H (2019)21 | Experimental study | no | no | no | no | no | not clear |
Graph 1Risk of bias
Graph 2Risk of bias summary
Characteristics of Excluded Studies
| Authors (Year) | Reason for Exclusion |
|---|---|
| Takenouchi K, Aso K (1964)23 | Animal study |
| Yussif NM, Koranayb NS, Abbass MMS (2017)24 | Animal study |
| Matsuda S, Shibayama H, Hisama M, Ohtsuki M, Iwaki M (2008)25 | |
| Panich U, Tangsupaanan V, Onkoksoong T, Kongtaphan K, Kasetsinsombat K, Akarasereenont P | |
| Lee SA, Son YO, Kook SH, Choi KC, Lee JC. (2011) 26 | |
| Taira N, Katsuyama Y, Yoshioka M, Okano Y, Masaki H (2017) 27 | |
| Katsuyama Y, Taira N, Yoshioka M, Okano Y, Masaki H (2018) 28 | |
| Taira N, Katsuyama Y, Yoshioka M, Okano Y, Morikawa T (2018)29 | |
| Yim S, Lee J, Jo H, Scholten J, Willingham R, Nicoll J, Baswan SM (2019) 30 | |
| Miao F, Su MY, Jiang S, Luo LF, Shi Y, Lei TC (2019) 31 | |
| Lee (2008) 32 | Case report |
| Sheel V, Purwar P, Dixit J. and Rai P (2015) 33 | Case report |
| Postaire E, Jungmann H, Bejot M, Heinrich U, Tronnier H. (1997) 34 | Used along with other agents |
| Broekmans WM, Vink AA, Boelsma E, Klöpping-Ketelaars WA, Tijburg LB, van’t Veer P, van Poppel G, Kardinaal AF. (2003) 35 | Used along with other agents |
| Hwang SW, Oh DJ, Lee D, Kim JW, Park SW (2009) 36 | Used along with other agent |
| Dormael RD, Bastien P, Sextius P, Gueniche A, Ye D, Tran C, | Used along with other agent |
| Ishikawa Y, Niwano T, Hirano S, Numano K, Takasima K, Imokawa G (2019) 38 | Used along with other agents |
| Kim J, Kim J, Lee YI, Almurayshid A, Jung JY, Lee JH. (2020) 39 | Used along with other agents |
| Rattanawiwatpong P, Wanitphakdeedecha R, Bumrungpert A, Maiprasert M (2020)40 | Used along with other agents |
| Huh CH, Seo KI, Park JY, Lim JG, Eun HC, Park KC (2003) 41 | Used in conjunction with Iontophoresis |
| Shaikh I, Mashood AA (2014) 42 | Used in conjunction with fluorescent pulsed light (FLP) |
| Yun IS, Yoo HS, Kim YO, Rah DK (2013) 43 | Used for scar reduction |
| Amirlak B, Mahedia M, Shah N (2016)44 | Used for scar reduction |